<DOC>
	<DOCNO>NCT02338518</DOCNO>
	<brief_summary>Chemotherapy important therapeutic method unresectable gastric cancer patient . However , currently establish standard chemotherapeutic regimen gastric cancer . The aim study compare efficacy toxicity SEEOX SOX regimens . The investigator estimate combine intravenous intra-arterial intensified SEEOX neoadjuvant chemotherapy may safe promise regimen unresectable gastric cancer patient .</brief_summary>
	<brief_title>Comparison SEEOX SOX Regimens Stage ⅢB/ⅢC Gastric Cancer Patients</brief_title>
	<detailed_description>Gastric cancer patient receive neoadjuvant chemotherapy would include study . They would receive combine intravenous intra-arterial intensified SEEOX neoadjuvant chemotherapy SOX regimen random . The efficacy toxicity two regimen would compare .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) score 02 Ambulatory male female , age 3070 year . Unresectable gastric cancer ( Tumors bulky nodal metastasis surround celiac artery branch invasion adjacent structure pancreas , omentum , esophagus , aorta consider unresectable ) Life expectancy 3 month Give write informed consent , understand patient right withdraw study time , without prejudice . Normal hepatic , renal , bone marrow function ( GPT &lt; 2 fold upper limit value ; white blood cell count &gt; 4000/dl , Tbil &lt; 1.5mg/dl , Cr &lt; 1.5 fold upper limit value ) Patients bear surgical procedure . Pregnant lactating woman . Previous cytotoxic chemotherapy , radiotherapy immunotherapy . History another malignancy within last five year . History uncontrolled seizure , central nervous system disorder psychiatric disability judge Investigator clinically significant precluding inform consent interfere compliance oral drug intake . Clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , New York Heart Association ( NYHA ) grade II great congestive heart failure serious cardiac arrhythmia require medication myocardial infarction within last 12 month . Organ allograft require immunosuppressive therapy . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Moderate severe renal impairment : serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . Hypersensitivity drug study regimen . With abdominal cavity implantation metastasis distant metastasis . Unwilling unable comply protocol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>